Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

1077 results about "Phospholipin" patented technology

Acylated uridine and cytidine and uses thereof

ActiveUS6258795B1No untoward pharmaceutical effectEfficient managementBiocideSugar derivativesDiseaseDiabetes mellitus
The invention relates to compositions comprising acyl derivatives of cytidine and uridine. The invention also relates to methods of treating hepatopathies, diabetes, heart disease, cerebrovascular disorders, Parkinson's disease, infant respiratory distress syndrome and for enhancement of phospholipid biosynthesis comprising administering the acyl derivatives of the invention to an animal.
Owner:WELLSTAT THERAPEUTICS

Environmentally friendly grease composition

An environmentally friendly grease composition is provided comprising (a) a vegetable oil and (b) a cellulose fiber. The grease may further comprise glycerin; a rust inhibitor; and / or a fatty acid ester, lecithin, phosphatidyl choline, or a combination thereof.
Owner:MONTANA STATE UNIVERSITY

Method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules

The invention discloses a method for extracting squalene by using camellia oleosa seeds as raw materials and tea oil and squalene soft capsules and relates to the technical field of biomedicine. The extraction method comprises the following process flows of material preparation, grinding, leaching, concentration, methyl esterification, complexant-borax reaction, macroporous resin chromatographic separation and purification, concentration, extraction, washing, concentration, preparation of squalene crude oil and supercritical carbon dioxide extraction, so that squalene essential oil with the squalene content of more than or equal to 80 percent is obtained. The tea oil and squalene soft capsules are prepared from the following raw materials in percentage by weight: 87 to 90 percent of squalene essential oil with the squalene content of more than or equal to 80 percent, 3 to 5 percent of polyethylene glycol 400, 2 to 3 percent of beewax and 2 to 5 percent of phospholipid. The raw material resources are wide. The prepared tea oil and squalene soft capsules not only can be used for medicine, but also can be used for food therapy, are particularly suitable for administration of treatment and food therapy of patients suffering from hepatitis, fatty liver, acute and chronic inflammation, tumor, chemotherapy, diabetes mellitus and cardio-cerebrovascular disease and have no toxic or side effects.
Owner:李文东

Full dry-mixing infant formula milk powder and preparation method of full dry-mixing infant formula milk powder

PendingCN104757123APromote digestion and absorptionMeet the needs of comprehensive growthMilk preparationBiotechnologyNucleotide
The invention provides full dry-mixing infant formula milk powder and a preparation method of the full dry-mixing infant formula milk powder. Auxiliaries of the infant formula milk powder comprise whey protein concentrate, galactooligosaccharide, fructo-oligose, docosahexaenoic acid, arachidonic acid, phospholipid, nucleotide, taurine, L-carnitine, probiotics, compound vitamin and compound mineral substances; the full dry-mixing infant formula milk powder is characterized in that the auxiliaries are pre-mixed with demineralized whey powder or skim milk powder to form a pre-mixture firstly, and the pre-mixture is totally mixed with other main ingredients to prepare the full dry-mixing infant formula milk powder. The full dry-mixing infant formula milk powder provided by the invention simulates humanisation productive infant formula milk powder, so that the digestive absorption of infants can be improved, and the infant intelligence development and the immunity of the infants can be improved. The infant formula milk powder prepared by using the method adopts uniform effective components and active components, stable in storage and transportation and low in production address selection requirement and suitable for being energetically popularized.
Owner:合生元(长沙)营养食品有限公司

Soybean phospholipid pressed candies and preparation method thereof

The invention provides soybean phospholipid pressed candies and a preparation method thereof. The soybean phospholipid pressed candies are prepared from the following raw materials in percentage by weight: 40 to 60 percent of sweetener or white granulated sugar and sweetener, 10 to 20 percent of soybean phospholipid powder, 10 to 30 percent of soybean milk powder, 1 to 10 percent of fruit powder,1 to 10 percent of vegetable powder, 5 to 35 percent of malto dextrin, 0 to 8 percent of complex vitamin and minerals, 0 to 10 percent of soybean compound nutritional factor mixture, 0 to 3 percent of flavoring essence, 0 to 0.3 percent of coloring agent and 0.5 to 2.5 percent of magnesium stearate. In the soybean phospholipid pressed candies, the added soybean phospholipid contains various active substances such as orgorganophosphorus, choline, inositol and the like, also contains essential fatty acid required by a human body, does not contain any cholesterol, and provides guarantee for metabolism and health life of the human body. The soybean phospholipid pressed candies have effects of resisting oxidation and ageing, reducing blood fat, promoting blood circulation, beautifying, eliminating brain fatigue, improving memory and the like, are suitable to be eaten by children and middle-aged and elderly people daily to promote mental development of the children and prevent dementia of the middle-aged and elderly people, and are also suitable to be eaten by workers daily to have the effects of regulating intestines and stomach and the like.
Owner:JIUSAN OILS & GRAINS IND GRP CO LTD

Method for preparing soybean separate protein by ultra-filter film separation technology

The preparation process of separate soybean protein includes the following steps: low temperature defatting bean, the first leaching, separating protein liquid from bean dregs, the second leaching, separating protein liquid from bean dregs, deairing, acid depositing, filterig with ultrafiltering film to obtain concentrated liquid, water washing, neutralizing, sterilizing, spray drying and spraying phospholipid to obtain the separate soybean protein product.
Owner:哈高科大豆食品有限责任公司

Monophosphoinositide proteoglycans-3 chemiluminescence immune analysis determination reagent kit and preparing method thereof

The invention relates to the medical field of immunoassay, more specially, the invention provides a chemiluminescent immunoassay detection kit for phosphatidylinositol proteoglycan-3(GPC-3) and a preparation method thereof, and realizes the simultaneous serological detection of GPC-3 N terminal and C-terminal protein with the chemiluminescent immunoassay method. The kit has the advantages of simple sampling, convenient detection and accurate and specific technical method. The invention adopts a biotin-strapavidin system to coat antibodies and improve the efficiency of antibody coating and the linear range of detection as well as sensitivity, and can be conveniently used for the tracing observation of early diagnosis or treatment effect for primary carcinoma of liver.
Owner:CHEMCLIN DIAGNOSTICS CO LTD

Sustained-release lipid pre-concentrate of cationic pharmacologically active substance and pharmaceutical composition comprising the same

Disclosed is a sustained-release lipid pre-concentrate, comprising: a) at least one liquid crystal former; b) at least one neutral phospholipid; c) at least one liquid crystal hardener; and d) at least one anionic anchoring agent, wherein the sustained-release pre-concentrate exists as a lipid liquid phase in the absence of aqueous fluid and forms into a liquid crystal upon exposure to aqueous fluid. The sustained-release lipid pre-concentrate is configured to enhance the sustained release of cationic pharmacologically active substance through ionic interaction between the anionic anchoring agent and the cationic pharmacologically active substance.
Owner:CHONG KUN DANG PHARMA CORP

Cationic phospholipid-polymer hybridized nanoparticle vaccine adjuvant of common-carrier antigen, MPLA (Monophosphoryl Lipid A) and IMQ (Imiquimod) as well as preparation method and application thereof

The invention relates to a cationic phospholipid-polymer hybridized nanoparticle vaccine adjuvant of a common-carrier antigen, MPLA (Monophosphoryl Lipid A) and IMQ (Imiquimod) as well as a preparation method and application thereof. The vaccine adjuvant is characterized in that the IMQ as a TLR7 agonist is loaded on a hydrophobic core; the MPLA as a TLR4 agonist is loaded in a phopholipid layer;cationic phospholipid DOTAP (1,2-dioleoy-3-trimethylammonium-propane) in the phopholipid layer is used for adsorbing an antigen; the antigen is protected through hybridized nanoparticles, and the ingestion of the antigen by dendritic cells is improved; immune response after antigen stimulation is improved remarkably through the TLR agonist, and cross-presentation of the antigen is improved remarkably. The hybridized nanoparticles as the vaccine adjuvant can load the antigen and different types of TLR agonists simultaneously, can deliver the antigen through a plurality of immune paths, and promotes the DC activation and maturation. The cross-presentation level is raised, a strong and powerful T-cell killing effect is achieved, cell factor secretion is induced, a long-term memory T-cell reaction is generated, and higher prevention capability for tumors is achieved.
Owner:INST OF BIOMEDICAL ENG CHINESE ACAD OF MEDICAL SCI

Using Targeted Radiotherapy (TRT) to Drive Anti-Tumor Immune Response to Immunotherapies

The disclosed method of treating a malignant solid tumor in a subject includes the steps of administering to the subject an immunomodulatory dose of a radioactive phospholipid ether metal chelate, a radiohalogenated phospholipid ether, or other targeted radiotherapy (TRT) agent that is differentially retained within malignant solid tumor tissue, and either (a) performing in situ tumor vaccination in the subject by introducing into at least one of the malignant solid tumors one or more agents capable of stimulating specific immune cells within the tumor microenvironment, or (b) performing immunotherapy in the subject by systemically administering to the subject an immunostimulatory agent, such as an immune checkpoint inhibitor. In a non-limiting example, the radioactive phospholipid ether metal chelate or radiohalogenated phospholipid ether has the formula:wherein R1 comprises a chelating agent that is chelated to a metal atom, wherein the metal atom is an alpha, beta or Auger emitting metal isotope with a half-life of greater than 6 hours and less than 30 days, or wherein R1 comprises a radioactive halogen isotope. In one such embodiment, a is 1, n is 18, m is 0, b is 1, and R2 is —N+(CH3)3.
Owner:WISCONSIN ALUMNI RES FOUND

Taxol nanoparticle freeze-drying preparation containing recombinant human serum albumin

The invention discloses a nanoparticle freeze-drying powder preparation containing recombinant human serum albumin. The preparation is prepared from the following components in mass percent: 0.05-5% of taxol, 0.1-50% of phospholipid, 1-60% of recombinant human serum albumin, 1-60% of freeze-drying supporting agent and 0.05-10% of PH regulating agent. In the invention, the average particle size of the obtained nanoparticles is less than 0.4mu m, and the obtained powder preparation is reproduced with water for injection, glucose and normal saline to form an injectable water solution the PH of which is 5.0-7.0, thereby greatly improving the industrialized value of the preparation.
Owner:YUANRONG BIOLOGICAL PHARMA WUXI CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products